Ratings TILT Holdings Inc.

Equities

TILT

CA88688R1047

End-of-day quote NEO Exchange Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.035 ^CAD	-12.50%		-22.22%	+16.67%

Mar. 14	Transcript : TILT Holdings Inc., Q4 2023 Earnings Call, Mar 14, 2024
Mar. 14	TILT Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TILT HOLDINGS INC.	+16.67%	9.91M		-
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes